X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PANACEA BIOTECH - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PANACEA BIOTECH CIPLA/
PANACEA BIOTECH
 
P/E (TTM) x 43.9 81.4 53.9% View Chart
P/BV x 3.6 1.8 200.0% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 CIPLA   PANACEA BIOTECH
EQUITY SHARE DATA
    CIPLA
Mar-17
PANACEA BIOTECH
Mar-14
CIPLA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs622149 418.2%   
Low Rs45882 556.9%   
Sales per share (Unadj.) Rs181.984.1 216.1%  
Earnings per share (Unadj.) Rs12.9-18.3 -70.3%  
Cash flow per share (Unadj.) Rs29.3-6.7 -437.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.783.7 186.0%  
Shares outstanding (eoy) m804.5161.25 1,313.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.4 216.4%   
Avg P/E ratio x42.0-6.3 -665.2%  
P/CF ratio (eoy) x18.4-17.2 -106.9%  
Price / Book Value ratio x3.51.4 251.4%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5167,074 6,142.1%   
No. of employees `00023.02.8 837.9%   
Total wages/salary Rs m26,3381,449 1,817.4%   
Avg. sales/employee Rs Th6,349.11,874.1 338.8%   
Avg. wages/employee Rs Th1,143.0527.0 216.9%   
Avg. net profit/employee Rs Th449.3-407.7 -110.2%   
INCOME DATA
Net Sales Rs m146,3025,154 2,838.8%  
Other income Rs m2,287100 2,291.5%   
Total revenues Rs m148,5895,254 2,828.4%   
Gross profit Rs m24,758-766 -3,230.8%  
Depreciation Rs m13,229711 1,860.7%   
Interest Rs m1,5941,503 106.0%   
Profit before tax Rs m12,222-2,881 -424.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-70-6 1,226.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,79817 10,700.0%   
Profit after tax Rs m10,354-1,121 -923.4%  
Gross profit margin %16.9-14.9 -113.8%  
Effective tax rate %14.7-0.6 -2,521.9%   
Net profit margin %7.1-21.8 -32.5%  
BALANCE SHEET DATA
Current assets Rs m87,3703,810 2,293.1%   
Current liabilities Rs m33,0818,365 395.5%   
Net working cap to sales %37.1-88.4 -42.0%  
Current ratio x2.60.5 579.9%  
Inventory Days Days87156 55.9%  
Debtors Days Days6267 92.7%  
Net fixed assets Rs m111,56714,480 770.5%   
Share capital Rs m1,60961 2,624.8%   
"Free" reserves Rs m123,645903 13,691.2%   
Net worth Rs m125,2545,127 2,442.9%   
Long term debt Rs m36,4545,832 625.1%   
Total assets Rs m209,53219,433 1,078.2%  
Interest coverage x8.7-0.9 -945.8%   
Debt to equity ratio x0.31.1 25.6%  
Sales to assets ratio x0.70.3 263.3%   
Return on assets %5.72.0 290.3%  
Return on equity %8.3-21.9 -37.8%  
Return on capital %8.53.6 233.8%  
Exports to sales %34.224.5 139.5%   
Imports to sales %8.310.2 81.9%   
Exports (fob) Rs m50,0501,264 3,960.3%   
Imports (cif) Rs m12,203525 2,325.2%   
Fx inflow Rs m51,0661,539 3,317.7%   
Fx outflow Rs m17,678942 1,876.6%   
Net fx Rs m33,388597 5,590.8%   
CASH FLOW
From Operations Rs m23,824599 3,975.9%  
From Investments Rs m-13,127-438 2,997.6%  
From Financial Activity Rs m-13,239-303 4,374.9%  
Net Cashflow Rs m-2,478-141 1,753.7%  

Share Holding

Indian Promoters % 16.0 74.5 21.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 0.6 2,033.3%  
FIIs % 23.7 1.3 1,823.1%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.6 111.0%  
Shareholders   161,166 10,259 1,571.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 24, 2017 10:36 AM

TRACK CIPLA

CIPLA - TORRENT PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS